June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Real-life effectiveness of Ranibizumab in RVO patients in a prospective, non-interventional trial over 12 months (OCEAN study)
Author Affiliations & Notes
  • Josep Callizo
    Ophthalmology, Georg-August University, Goettingen, Germany
  • Thomas Bertelmann
    Ophthalmology, Georg-August University, Goettingen, Germany
  • Jessica Voegeler
    Novartis Pharma, Nuernberg, Germany
  • Steffen Schmitz-Valckenberg
    Ophthalmology, University of Bonn, Bonn, Germany
  • Georg Spital
    Ophthalmology, St. Franziskus-Hospital, Muenster, Germany
  • Nicolas Feltgen
    Ophthalmology, Georg-August University, Goettingen, Germany
  • Sandra Liakopoulos
    Ophthalmology, University Hospital of Cologne, Cologne, Germany
  • Focke Ziemssen
    Ophthalmology, Eberhard-Karls University of Tuebingen, Tuebingen, Germany
  • Footnotes
    Commercial Relationships   Josep Callizo, Allergan (R), Bayer Healthcare (R), Novartis (R); Thomas Bertelmann, Alcon (F), Alcon (R), Alimera Science (F), Alimera Science (R), Allergan (F), Allergan (R), Bayer Healthcare (F), Bayer Healthcare (R), Novartis (F), Novartis (R); Jessica Voegeler, Novartis (E); Steffen Schmitz-Valckenberg, Alcon (C), Alcon (F), Allergan (F), Allergan (R), Bayer Healthcare (F), Bayer Healthcare (R), Carl Zeis MediTec (F), Formycon (F), Genentech/Roche (C), Genentech/Roche (F), Genentech/Roche (R), Heidelberg Engineering (F), Heidelberg Engineering (R), Novartis (C), Novartis (F), Optos (F); Georg Spital, Allergan (R), Bayer Healthcare (R), Heidelberg Engineering (R), Novartis (F), Novartis (R), Pfizer (R); Nicolas Feltgen, Alimera Science (F), Alimera Science (C), Alimera Science (R), Allergan (F), Allergan (R), Bayer Healthcare (F), Bayer Healthcare (R), Heidelberg Engineering (R), Novartis (F), Novartis (R), Pfizer (F), Roche/Genentech (F); Sandra Liakopoulos, Allergan (R), Bayer Healthcare (R), Heidelberg Engineering (R), Novartis (C), Novartis (R); Focke Ziemssen, Alcon (R), Alimera Science (C), Allergan (C), Allergan (R), Bayer Healthcare (C), Bayer Healthcare (R), Biogen (R), Boehringer-Ingelheim (C), Novartis (C), Novartis (R)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3674. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Josep Callizo, Thomas Bertelmann, Jessica Voegeler, Steffen Schmitz-Valckenberg, Georg Spital, Nicolas Feltgen, Sandra Liakopoulos, Focke Ziemssen; Real-life effectiveness of Ranibizumab in RVO patients in a prospective, non-interventional trial over 12 months (OCEAN study). Invest. Ophthalmol. Vis. Sci. 2017;58(8):3674.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The non-interventional OCEAN trial recruited retinal vein occlusion (RVO) patients in order to collect prospective data in a real-life setting. Randomized controlled trials (RCTs) have proven the beneficial effect of vascular endothelial growth factor (VEGF) inhibition with Ranibizumab in several indications including central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). Analysis of this study will allow a better understanding of relevant hurdles and barriers as well as the role of OCT imaging under Ranibizumab treatment.

Methods : In the non-interventional, prospective OCEAN study (NCT02194803) 5.779 patients were observed over 24 months. Herein we report the 12-month interim analysis of 744 patients diagnosed with RVO (52% female/ 48% male) with an average age of 70.9 years. The following data were recorded and analyzed: number of visits, visual acuity, number of injections, the use of diagnostic tools (OCT, fluorescein angiography) and adverse events.

Results : RVO patients received an average of 4.7 injections during the first year, while undergoing an average of 9.8 BCVA assessments and 4.3 OCT examinations. The average gain in BCVA was 12.3 ETDRS letters at 12 months. Moreover, 148 treatment-naive BRVO patients even gained on average 15.1 ETDRS letters and 87 treatment-naive CRVO gained on average 9.1 letters.
When more than 6 OCTs were performed within the first year, a higher number of patients gained ≥ 5 letters (63.6%, n=117) in comparison with patients with one or none OCT examination (50.3%, n=102). The mean decrease in central retinal thickness was 166 µm. No new safety signals were identified.
An update of 24-month data will be presented.

Conclusions : A 12-month observational period of the OCEAN trial clearly shows beneficial effects of Ranibizumab on BRVO and CRVO patients. The presented results indicate that the underutilization of diagnostic capabilities might accompany a possible undertreatment. Higher rates of OCT examinations were associated with better VA outcomes in RVO patients. This observation underlines the importance of additional measures improving adherence to and persistence of anti-VEGF treatment.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×